Nothing
# @file Data.R
#
# Copyright 2022 Observational Health Data Sciences and Informatics
#
# This file is part of EmpiricalCalibration
#
# Licensed under the Apache License, Version 2.0 (the "License");
# you may not use this file except in compliance with the License.
# You may obtain a copy of the License at
#
# http://www.apache.org/licenses/LICENSE-2.0
#
# Unless required by applicable law or agreed to in writing, software
# distributed under the License is distributed on an "AS IS" BASIS,
# WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied.
# See the License for the specific language governing permissions and
# limitations under the License.
#' Incidence rate ratios from Self-Controlled Case Series
#'
#' @details
#' A dataset containing the incidence rate ratios (and standard errors) produced using a
#' Self-Controlled Case Series (SCCS) design. The outcome is upper GI bleeding, the drug of interest
#' (groundTruth = 1) is sertraline. Also included are 45 negative control drugs, for which we believe
#' there to be no causal relation with upper GI bleeding. We used a database of medical records from
#' general practices in the USA, the General Electric (GE) Centricity database, which contains data on
#' 11.2 million subjects. We restricted on study period (start of 1990 through November 2003), age
#' requirements (18 years or older), available time prior to event (180 days), and risk definition
#' window (30 days following the prescription). Time 30 days prior to the first prescription was
#' removed to account for possible contra-indications. Cases of upper GI bleeding were identified on
#' the basis of the occurrence of ICD-9 diagnosis codes in the problem list. These codes pertain to
#' esophageal, gastric, duodenal, peptic, and gastrojejunal ulceration, perforation, and hemorrhage,
#' as well as gastritis and non-specific gastrointestinal hemorrhage. For more information on this set
#' see Schuemie et al (2014).
#'
#' @docType data
#' @keywords datasets
#' @name sccs
#' @usage
#' data(sccs)
#' @format
#' A data frame with 46 rows and 4 variables: \describe{ \item{drugName}{Name of the drug}
#' \item{groundTruth}{Whether the drug is a positive (1) or negative (0) control} \item{logRr}{The log
#' of the incidence rate ratio} \item{seLogRr}{The standard error of the log of the incidence rate
#' ratio} }
#' @references
#' Schuemie MJ, Ryan PB, Dumouchel W, Suchard MA, Madigan D. Interpreting observational studies: why
#' empirical calibration is needed to correct p-values. Statistics in Medicine 33(2):209-18,2014
NULL
#' Odds ratios from a case-control design
#'
#' @details
#' A dataset containing the odds ratios (and standard errors) produced using a case-control design.
#' The outcome is upper GI bleeding, the drug of interest (groundTruth = 1) is sertraline. Also
#' included are 46 negative control drugs, for which we believe there to be no causal relation with
#' upper GI bleeding. We used a database of medical records from general practices in the USA, the
#' General Electric (GE) Centricity database, which contains data on 11.2 million subjects. We
#' restricted on study period (start of 1990 through November 2003), age requirements (18 years or
#' older), available time prior to event (180 days), number of controls per case (6), and risk
#' definition window (30 days following the prescription). Controls were matched on age and sex. Cases
#' of upper GI bleeding were identified on the basis of the occurrence of ICD-9 diagnosis codes in the
#' problem list. These codes pertain to esophageal, gastric, duodenal, peptic, and gastrojejunal
#' ulceration, perforation, and hemorrhage, as well as gastritis and non-specific gastrointestinal
#' hemorrhage. For more information on this set see Schuemie et al (2014).
#'
#' @docType data
#' @keywords datasets
#' @name caseControl
#' @usage
#' data(caseControl)
#' @format
#' A data frame with 47 rows and 4 variables: \describe{ \item{drugName}{Name of the drug}
#' \item{groundTruth}{Whether the drug is a positive (1) or negative (0) control} \item{logRr}{The log
#' of the incidence rate ratio} \item{seLogRr}{The standard error of the log of the incidence rate
#' ratio} }
#' @references
#' Schuemie MJ, Ryan PB, Dumouchel W, Suchard MA, Madigan D. Interpreting observational studies: why
#' empirical calibration is needed to correct p-values. Statistics in Medicine 33(2):209-18,2014
NULL
#' Relative risks from a new-user cohort design
#'
#' @details
#' A dataset containing the relative risks (and standard errors) produced using a new-user cohort
#' design. The outcome is acute liver injury, the drug of interest (groundTruth = 1) is Isoniazid Also
#' included are 30 negative control drugs, for which we believe there to be no causal relation with
#' acute liver injury. We used the Thomson MarketScan Medicare Supplemental Beneficiaries database,
#' which contains data on 4.6 million subjects. We selected two groups (cohorts): (1) all subjects
#' exposed to isoniazid and (2) all subjects having the ailment for which isoniazid is indicated, in
#' this case tuberculosis, and having received at least one drug that is not known to cause acute
#' liver injury. We removed all subjects who belonged to both groups and subjects for which less than
#' 180 days of observation time was available prior to their first exposure to the drug in question.
#' Acute liver injury was identified on the basis of the occurrence of ICD-9-based diagnosis codes
#' from inpatient and outpatient medical claims and was defined broadly on the basis of codes
#' associated with hepatic dysfunction, as have been used in prior observational database studies. The
#' time at risk was defined as the length of exposure + 30 days, and we determined whether subjects
#' experienced an acute liver injury during their time at risk. Using propensity score stratification,
#' the cohorts were divided over 20 strata, and an odds ratio over all strata was computed using a
#' Mantel-Haenszel test. The propensity score was estimated using Bayesian logistic regression using
#' all available drug, condition, and procedure covariates occurring in the 180 days prior to first
#' exposure, in addition to age, sex, calendar year of first exposure, Charlson index, number of
#' drugs, number of visit days, and number of procedures. For more information on this set see
#' Schuemie et al (2014).
#'
#' @docType data
#' @keywords datasets
#' @name cohortMethod
#' @usage
#' data(cohortMethod)
#' @format
#' A data frame with 31 rows and 4 variables: \describe{ \item{drugName}{Name of the drug}
#' \item{groundTruth}{Whether the drug is a positive (1) or negative (0) control} \item{logRr}{The log
#' of the incidence rate ratio} \item{seLogRr}{The standard error of the log of the incidence rate
#' ratio} }
#' @references
#' Schuemie MJ, Ryan PB, Dumouchel W, Suchard MA, Madigan D. Interpreting observational studies: why
#' empirical calibration is needed to correct p-values. Statistics in Medicine 33(2):209-18,2014
NULL
#' Relative risks from an unadjusted new-user cohort design
#'
#' @details
#' A dataset containing the incidence rate ratios (and standard errors) produced using a new-user
#' cohort design that compares new-users of dabigatran to new-users of warfarin for the outcome of
#' GI hemorrhage. The dataset includes estimates both for the outcome of interest as well as negative
#' and positive control outcomes. Subjects are required to have 183 days of continuous observation prior to
#' initiating treatment, a prior diagnosis of atrial fibrillation, and are required to have no prior
#' exposure to either dabigatran or warfarin. The study computes an incidence rate ratio without
#' any adjustment for confounders. Time at risk is defined as the time on the drug. The original
#' study (Southworth 2013) uses the 'Mini-Sentinel Database'. For our replication, we use the Optum
#' databases since both databases are US insurance claims databases. We analyzed 5,982
#' dabigatran-exposed and 19,155 warfarin-exposed subjects. For more information on this set see
#' Schuemie et al (2017).
#'
#' @docType data
#' @keywords datasets
#' @name southworthReplication
#' @usage
#' data(southworthReplication)
#' @format
#' A data frame with 174 rows and 4 variables: \describe{ \item{outcomeName}{Name of the outcome}
#' \item{trueLogRr}{The log of the true effect size. Only provided for negative and positive controls,
#' is NA for the outcome of interest (GI bleeding).} \item{logRr}{The log of the incidence rate ratio} \item{seLogRr}{
#' The standard error of the log of the incidence rate ratio} }
#'
#' @references
#' Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Empirical confidence interval calibration
#' for population-level effect estimation studies in observational healthcare data. Proc Natl Acad Sci
#' U S A. 2018 Mar 13;115(11):2571-2577
#'
#' Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl
#' J Med 368(14):1272-1274, 2013
NULL
#' Relative risks from an adjusted new-user cohort design
#'
#' @details
#' A dataset containing the incidence rate ratios (and standard errors) produced using a new-user
#' cohort design that compares new-users of dabigatran to new-users of warfarin for the outcome of
#' GI hemorrhage. The dataset includes estimates both for the outcome of interest as well as negative
#' and positive control outcomes. Subject are required to have 183 days of continuous observation
#' prior to initiating treatment, be at least 65 years old at index date, and are required to have
#' no prior exposure to warfarin or dabigatran (or any other novel anticoagulant). Furthermore,
#' subjects are required to use the treatment for the indication of atrial fibrillation or atrial
#' flutter, which is enforced by requiring a prior diagnosis of atrial fibrillation or flutter,
#' and no prior diagnosis of other indications. Propensity scores are generated by fitting a model
#' for predicting treatment assignment based on baseline patient characteristics, and are used to
#' perform one-on-one matching. Hazard ratios are estimated through a Cox regression on the matched
#' population. Time-at-risk is defined as starting on the day after initiating treatment and stopping
#' when treatment is stopped, when the outcome occurs, or observation time ends, whichever comes first.
#' The original study (Graham et al 2016) uses the Medicare database. For our replication, we use the
#' Truven Medicare Supplementary Beneficiaries database. We analyze 15,796 dabigatran-exposed and 15,796
#' warfarin-exposed subjects. For more information on this set see Schuemie et al (2017).
#'
#' @docType data
#' @keywords datasets
#' @name grahamReplication
#' @usage
#' data(grahamReplication)
#' @format
#' A data frame with 126 rows and 4 variables: \describe{ \item{outcomeName}{Name of the outcome}
#' \item{trueLogRr}{The log of the true effect size. Only provided for negative and positive controls,
#' is NA for the outcome of interest (GI bleeding).} \item{logRr}{The log of the incidence rate ratio} \item{seLogRr}{
#' The standard error of the log of the incidence rate ratio} }
#'
#' @references
#' Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Empirical confidence interval calibration
#' for population-level effect estimation studies in observational healthcare data. Proc Natl Acad Sci
#' U S A. 2018 Mar 13;115(11):2571-2577
#'
#' Graham DJ, Reichman ME, Wernecke M, Hsueh YH, Izem R, Southworth MR, Wei Y, Liao J, Goulding MR, Mott K,
#' Chillarige Y, MaCurdy TE, Worrall C, Kelman JA. Stroke, Bleeding, and Mortality Risks in Elderly Medicare
#' Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA Intern
#' Med 176(11):1662-1671, 2016
NULL
Any scripts or data that you put into this service are public.
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.